Addressing the Challenges of Alzheimer’s Agitation

Advancing IGC-AD1 in the CALMA trial—supporting patients and caregivers through science and compassion. 

How is

IGC Pharma
fighting agitation?

IGC Pharma is advancing IGC-AD1, a cannabinoid-based investigational therapy in a double-blind Phase 2 trial (CALMA), designed to reduce agitation and improve quality of life.

Our Science, Our Commitment

What is CALMA?

CALMA Clinical Trial

CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and potential efficacy of IGC-AD1 for treating agitation in participants with dementia due to Alzheimer's disease.

Explore CALMA →

What is IGC-AD1?

IGC-AD1 Medication

IGC-AD1 is IGC Pharma’s lead candidate—a partial CB1 receptor agonist with anti-inflammatory action, designed to address agitation associated with Alzheimer’s disease.

Learn About IGC‑AD1 →

What is MINT-AD?

MINT-AD AI Platform

MINT-AD is IGC Pharma’s AI-powered platform that leverages multimodal data to support early Alzheimer’s detection and improve understanding of disease progression.

Discover MINT‑AD →

What is TGR-63?

IGC-AD1 Medication

A small molecule designed to inhibit amyloid plaque aggregation in neuronal tissue, with the ability to cross the blood–brain barrier and demonstrated pre-clinical behavioral efficacy.

Learn About TGR-63 →

Latest Press Releases

Explore how IGC Pharma’s data, trials, and milestones are shaping a brighter future for Alzheimer’s care.    

IGC Pharma’s Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer’s Disease 

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer’s Trial 

IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology 

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial

Together, we’re turning research into resilience, and innovation into care for millions worldwide.

0 Million

Americans projected to have Alzheimer’s disease by 2043

0 Million

Americans projected to have Alzheimer’s disease by 2060

0 th

Leading cause of death among Americans aged 65+

$ 0 Trillion

Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found.

Pipeline

IGC Pharma’s pipeline bridges breakthroughs from AI-enhanced
early detection to IGC-AD1 and beyond, advancing Alzheimer’s
treatment frontiers.

In-depth insights,
real impact

“Science Spotlight” reveals our latest Alzheimer’s research, breakthroughs, and care innovations.     

Investing in the Future:

IGC Pharma stands with families and vulnerable groups, investing in research, education, advocacy and Alzheimer’s awareness.